# Lutathera and ASTX727 in Neuroendocrine Tumours

> **NCT05178693** · PHASE1 · RECRUITING · sponsor: **Imperial College London** · enrollment: 27 (estimated)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** ASTX727
- **RADIATION:** Lutathera

## Key facts

- **NCT ID:** NCT05178693
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-25
- **Primary completion:** 2026-06-30
- **Final completion:** 2029-02-28
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2025-11-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05178693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05178693, "Lutathera and ASTX727 in Neuroendocrine Tumours". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05178693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*